Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,018 recalls, newest first

Class II · Moderate risk

Epi-Caine

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Terminated Failed specification Pine Pharmaceuticals, LLC NDC 69194-0948-1 D-0130-2023
Class III · Low risk

Timolol Maleate Ophthalmic Solution

Failed Stability Specifications: Out of specification for weight loss at the 18-month stability timepoint and projected weight loss of 21.1% at shelf life.

Terminated Stability / shelf life Apotex Corp. NDC 60505-1005-4 D-0093-2023
Class I · High risk

Epinephrine

Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product

Terminated Failed specification Spectrum Laboratory Products, Inc. D-0180-2023
Class I · High risk

Epinephrine

Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product

Terminated Failed specification Spectrum Laboratory Products, Inc. D-0179-2023
Class II · Moderate risk

Ganciclovir for Injection

Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

Terminated Labeling / mix-up Hikma Pharmaceuticals USA Inc. NDC 0143-9299-01 D-0090-2023
Class II · Moderate risk

Rifampin Capsules USP

Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-659-06 D-0100-2023
Class II · Moderate risk

Menastil

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. NDC 66233-711-01 D-0084-2023
Class II · Moderate risk

ProSirona

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. NDC 66233-712-01 D-0083-2023
Class II · Moderate risk

Neuroquell

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. D-0082-2023
Class II · Moderate risk

Neuroquell Plus

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. D-0081-2023
Class II · Moderate risk

Quinapril Tablets USP

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Terminated Nitrosamine impurity Lupin Pharmaceuticals Inc. NDC 68180-558-09 D-0089-2023
Class II · Moderate risk

Quinapril Tablets USP

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Terminated Nitrosamine impurity Lupin Pharmaceuticals Inc. NDC 68180-554-09 D-0088-2023
Class I · High risk

Advil Liqui Gels

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0183-2023

Recalls by year